|
Please
login
to be able to add spectra, identifiers, links and publications.
|
|
|
ChemSpider ID: |
62060
|
|
Empirical Formula: |
C15H22O5
|
|
Molecular Weight: |
282.3322
|
|
Nominal Mass: |
282
Da
|
|
Average Mass: |
282.3322
Da
|
|
Monoisotopic Mass: |
282.146724
Da
|
|
|
|
Systematic Name: |
|
|
SMILES: |
O=C3O[C@@H]4O[C@@]1(OO[C@@]42[C@@H](CC1)[C@H](C)CC[C@H]2[C@H]3C)C
|
|
InChI: |
InChI=1/C15H22O5/c1-8-4-5-11-9(2)12(16)17-13-15(11)10(8)6-7-14(3,18-13)19-20-15/h8-11,13H,4-7H2,1-3H3/t8-,9-,10+,11+,13-,14-,15-/m1/s1
|
|
InChIKey: |
BLUAFEHZUWYNDE-NNWCWBAJBD
|
|
Std. InChI: |
InChI=1S/C15H22O5/c1-8-4-5-11-9(2)12(16)17-13-15(11)10(8)6-7-14(3,18-13)19-20-15/h8-11,13H,4-7H2,1-3H3/t8-,9-,10+,11+,13-,14-,15-/m1/s1
|
|
Std. InChIKey: |
BLUAFEHZUWYNDE-NNWCWBAJSA-N
|
Artemisinin () is a drug used to treat multi-drug resistant strains of falciparum malaria. The compound (a sesquiterpene lactone) is isolated from the plant Artemisia annua. Not all plants of this species contain artemisinin. Apparently it is only produced when the plant is subjected to certain conditions, most likely biotic or abiotic stress. It can be synthesized from artemisinic acid. The drug is derived from a herb used in Chinese traditional medicine, though it is usually chemically modified and combined with other medications.
Use of the drug by itself as a monotherapy is explicitly discouraged by the World Health Organization as there have been signs that malarial parasites are developing resistance to the drug. Combination therapies that include artemisinin are the preferred treatment for malaria and are both effective and well tolerated in patients. The drug is also being studied as a treatment for cancer.
Read more... or Edit at Wikipedia...
Links & References
Srivastava Suchita.
Biotransformation of Artemisinin Mediated through Fungal Strains for Obtaining Derivatives with Novel Activities, Scientia Pharmaceutica, 2009
|
|
Kato et al..
Gene expression signatures and small molecule compounds link a protein kinase to Plasmodium falciparum motility, Nature Chemical Biology, doi: 10.1038/nchembio.87, published online 27 April 2008.
|
|
|
Validated by Experts, Validated by Users, Non-Validated, Removed by Users,
Redirected by Users, Redirect Approved by Experts
(3R,5aS,6R,8aS,9R,12S,12aR)-3,6,9-trimethyloctahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10(3H)-one
(4S,5R,8S,9R,12S,13R)-1,5,9-Trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.0~4,13~.0~8,13~]hexadecan-10-on
(4S,5R,8S,9R,12S,13R)-1,5,9-Trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.0~4,13~.0~8,13~]hexadecan-10-one
(4S,5R,8S,9R,12S,13R)-1,5,9-Triméthyl-11,14,15,16-tétraoxatétracyclo[10.3.1.0~4,13~.0~8,13~]hexadécan-10-one
(5aS,6R,8aS,9R,12S,12aR)-3,6,9-trimethyloctahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10(3H)-one
[3R-(3a,5ab,6b,8ab,9a,12b,12aR*)]-Octahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10(3H)-one
3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10(3H)-one, octahydro-3,6,9-trimethyl-, (3R,5aS,6R,8aS,9R,12S,12aR)-
3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10(3H)-one, octahydro-3,6,9-trimethyl-, (5aS,6R,8aS,9R,12S,12aR)-
Artemisinin [INN]
QHS
More...
(+)-artemisinin
(1R,4S,5R,8S,9R,12S,13R)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-one
(3R,5aS,6R,8aS,9R,12S,12aR)-3,6,9-trimethyloctahydro-3,12-epoxypyrano[4,3-j][1,2]benzodioxepin-10(3H)-one
(3R,5aS,6R,8aS,9R,12S,12aR)-Octahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin-10(3H)-one
(3R,5aS,6R,8aS,9R,12S,12aR)-Octahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10(3H)-one
(Artemisinin)1,5,9-trimethyl-(1R,4S,5R,8S,9R,12S,13R)-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-one
1,5,9-trimethyl-(1R,4S,5R,8S,9R,12S,13R)-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-one
1,5,9-trimethyl-(1R,4S,5R,8S,9R,12S,13R)-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-one (Arteminisin, qinghaosu, arteannuin)
1,5,9-trimethyl-(1R,4S,5R,8S,9R,12S,13R)-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-one(artemisinin)
1,5,9-trimethyl-(1R,4S,5R,9R,12S,13R)-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-one
1,5,9-trimethyl-(1S,4S,5R,8S,9R,12S,13S)-11,15,16-trioxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-one
1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-one
1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-one(Artemisinin(qinghaosu))
3,12-Epoxy-12H-pyranol(4,3-j)-1,2-benzodioxepin-10(3H)-one, octahydro-3,6,9-trimethyl-, (3-alpha,5a-beta,6-beta,8a-beta,9-alpha,12-beta,12aR*)-(+)-
63968-64-9
[RN]
Arteannuin
Artemisia annua L., extract
Artemisine
Artemisinin
[Wiki]
Artemisinin (qinghaosu)-related trioxane
Artemisinin;(+)-Arteannuin;Qinghaosu
Artemisinina
[Spanish]
Artemisinine
Artemisininum
[Latin]
Artesin
Cotexin
Deoxoartemisitene derivative
Huanghuahaosu
Octahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin-10(3H)-one
Octahydro-3-ethyl-9-methyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10(3H)-one
Qing Hau Sau
Qing Hau Sau [Chinese]
Qing Hau SU
Qinghaosu
[Wiki]
Qinghaosu [Chinese]
Qinghosu
quing hau sau
TL8004521
Less...
Validated by Experts, Validated by Users, Non-Validated, Removed by Users,
Redirected by Users, Redirect Approved by Experts
|
ACD/LogP: |
2.27
|
# of Rule of 5 Violations: |
0
|
|
ACD/LogD (pH 5.5): |
2.27
|
ACD/LogD (pH 7.4): |
2.27
|
|
ACD/BCF (pH 5.5): |
31.21
|
ACD/BCF (pH 7.4): |
31.21
|
|
ACD/KOC (pH 5.5): |
408.53
|
ACD/KOC (pH 7.4): |
408.53
|
|
#H bond acceptors: |
5
|
#H bond donors: |
0
|
|
#Freely Rotating Bonds: |
0
|
Polar Surface Area: |
53.99
Å2
|
|
Index of Refraction: |
1.533
|
Molar Refractivity: |
70.31
cm3
|
|
Molar Volume: |
226.4
cm3
|
Polarizability: |
27.87
10-24cm3
|
|
Surface Tension: |
43.5
dyne/cm
|
Density: |
1.24
g/cm3
|
|
Flash Point: |
172
°C
|
Enthalpy of Vaporization: |
63.93
kJ/mol
|
|
Boiling Point: |
389.9
°C at 760 mmHg
|
Vapour Pressure: |
2.76E-06
mmHg at 25°C
|
Log Octanol-Water Partition Coef (SRC):
Log Kow (KOWWIN v1.67 estimate) = 2.85
Log Kow (Exper. database match) = 2.90
Exper. Ref: Avery, MA et al. (1995)
Boiling Pt, Melting Pt, Vapor Pressure Estimations (MPBPWIN v1.42):
Boiling Pt (deg C): 379.33 (Adapted Stein & Brown method)
Melting Pt (deg C): 132.75 (Mean or Weighted MP)
VP(mm Hg,25 deg C): 2.18E-006 (Modified Grain method)
Subcooled liquid VP: 2.63E-005 mm Hg (25 deg C, Mod-Grain method)
Water Solubility Estimate from Log Kow (WSKOW v1.41):
Water Solubility at 25 deg C (mg/L): 51.85
log Kow used: 2.90 (expkow database)
no-melting pt equation used
Water Sol Estimate from Fragments:
Wat Sol (v1.01 est) = 9.8081 mg/L
ECOSAR Class Program (ECOSAR v0.99h):
Class(es) found:
Esters
Peroxy Acids
Henrys Law Constant (25 deg C) [HENRYWIN v3.10]:
Bond Method : 4.92E-009 atm-m3/mole
Group Method: Incomplete
Henrys LC [VP/WSol estimate using EPI values]: 1.562E-008 atm-m3/mole
Log Octanol-Air Partition Coefficient (25 deg C) [KOAWIN v1.10]:
Log Kow used: 2.90 (exp database)
Log Kaw used: -6.696 (HenryWin est)
Log Koa (KOAWIN v1.10 estimate): 9.596
Log Koa (experimental database): None
Probability of Rapid Biodegradation (BIOWIN v4.10):
Biowin1 (Linear Model) : 0.0721
Biowin2 (Non-Linear Model) : 0.0219
Expert Survey Biodegradation Results:
Biowin3 (Ultimate Survey Model): 2.2825 (weeks-months)
Biowin4 (Primary Survey Model) : 3.3527 (days-weeks )
MITI Biodegradation Probability:
Biowin5 (MITI Linear Model) : 0.4950
Biowin6 (MITI Non-Linear Model): 0.1061
Anaerobic Biodegradation Probability:
Biowin7 (Anaerobic Linear Model): -0.4393
Ready Biodegradability Prediction: NO
Hydrocarbon Biodegradation (BioHCwin v1.01):
Structure incompatible with current estimation method!
Sorption to aerosols (25 Dec C)[AEROWIN v1.00]:
Vapor pressure (liquid/subcooled): 0.00351 Pa (2.63E-005 mm Hg)
Log Koa (Koawin est ): 9.596
Kp (particle/gas partition coef. (m3/ug)):
Mackay model : 0.000856
Octanol/air (Koa) model: 0.000968
Fraction sorbed to airborne particulates (phi):
Junge-Pankow model : 0.03
Mackay model : 0.0641
Octanol/air (Koa) model: 0.0719
Atmospheric Oxidation (25 deg C) [AopWin v1.92]:
Hydroxyl Radicals Reaction:
OVERALL OH Rate Constant = 43.2548 E-12 cm3/molecule-sec
Half-Life = 0.247 Days (12-hr day; 1.5E6 OH/cm3)
Half-Life = 2.967 Hrs
Ozone Reaction:
No Ozone Reaction Estimation
Fraction sorbed to airborne particulates (phi): 0.047 (Junge,Mackay)
Note: the sorbed fraction may be resistant to atmospheric oxidation
Soil Adsorption Coefficient (PCKOCWIN v1.66):
Koc : 1206
Log Koc: 3.081
Aqueous Base/Acid-Catalyzed Hydrolysis (25 deg C) [HYDROWIN v1.67]:
Rate constants can NOT be estimated for this structure!
Bioaccumulation Estimates from Log Kow (BCFWIN v2.17):
Log BCF from regression-based method = 1.533 (BCF = 34.12)
log Kow used: 2.90 (expkow database)
Volatilization from Water:
Henry LC: 4.92E-009 atm-m3/mole (estimated by Bond SAR Method)
Half-Life from Model River: 2E+005 hours (8332 days)
Half-Life from Model Lake : 2.182E+006 hours (9.09E+004 days)
Removal In Wastewater Treatment:
Total removal: 4.92 percent
Total biodegradation: 0.12 percent
Total sludge adsorption: 4.81 percent
Total to Air: 0.00 percent
(using 10000 hr Bio P,A,S)
Level III Fugacity Model:
Mass Amount Half-Life Emissions
(percent) (hr) (kg/hr)
Air 0.034 5.94 1000
Water 14.1 900 1000
Soil 85.6 1.8e+003 1000
Sediment 0.259 8.1e+003 0
Persistence Time: 1.6e+003 hr
Descriptors:
0, 0, 0, 0, 0, 0, 0, 8, 1, 0, 0, 0, 21, 0, 1, 0, 0, 2, 1, 0, 0, 0, 0, 0
| Category | Target | PDB Code | LASSO Score |
| Metalloenzymes | ACE, angiotensin-converting enzyme | 1o86 | 0.03 |
| Nuclear Hormone Receptors | PPARg, peroxisome proliferator activated receptor | 1fm9 | 0.03 |
| Kinases | SRC, tyrosine kinase SRC | 2src | 0.01 |
| Other Enzymes | HMGR, hydroxymethylglutaryl-CoA reductase | 1hw8 | 0.01 |
| Other Enzymes | HIVPR, HIV protease | 1hpx | 0.01 |
| Metalloenzymes | PDE5, phosphodiesterase 5 | 1xp0 | 0.01 |
| Nuclear Hormone Receptors | MR, mineralocorticoid receptor | 2aa2 | 0.01 |
| Kinases | TK, thymidine kinase | 1kim | 0.01 |
| Other Enzymes | COX-1, cyclooxygenase-1 | 1p4g | 0.01 |
| Other Enzymes | PARP, poly(ADP-ribose) polymerase | 1efy | 0.01 |
| Other Enzymes | PNP, purine nucleoside phosphorylase | 1b8o | 0.00 |
| Other Enzymes | AmpC, AmpC beta-lactamase | 1xgj | 0.00 |
| Other Enzymes | ALR2, aldose reductase | 1ah3 | 0.00 |
| Nuclear Hormone Receptors | ER, estrogen receptor; agonist | 1l2i | 0.00 |
| Serine Proteases | Thrombin | 1ba8 | 0.00 |
| Nuclear Hormone Receptors | PR, progesterone receptor | 1sr7 | 0.00 |
| Folate Enzymes | DHFR, dihydrofolate reductase | 3dfr | 0.00 |
| Other Enzymes | HIVRT, HIV reverse transcriptase | 1rt1 | 0.00 |
| Kinases | VEGFr2, vascular endothelial growth factor receptor | 1vr2 | 0.00 |
| Other Enzymes | GPB, glycogen phosphorylase | 1a8i | 0.00 |
| Nuclear Hormone Receptors | RXRa, retinoic X receptor R | 1mvc | 0.00 |
| Other Enzymes | SAHH, S-adenosyl-homocysteine hydrolase | 1a7a | 0.00 |
| Kinases | FGFr1, fibroblast growth factor receptor kinase | 1agw | 0.00 |
| Other Enzymes | NA, neuraminidase | 1a4g | 0.00 |
| Kinases | CDK2, cyclindependent kinase 2 | 1ckp | 0.00 |
| Nuclear Hormone Receptors | AR, androgen receptor | 1xq2 | 0.00 |
| Kinases | P38 MAP, P38 mitogen activated protein | 1kv2 | 0.00 |
| Other Enzymes | AChE, acetylcholinesterase | 1eve | 0.00 |
| Nuclear Hormone Receptors | GR, glucocorticoid receptor | 1m2z | 0.00 |
| Kinases | PDGFrb, platelet derived growth factor receptor kinase | N/A | 0.00 |
| Folate Enzymes | GART, glycinamide ribonucleotide transformylase | 1c2t | 0.00 |
| Nuclear Hormone Receptors | ER, estrogen receptor; antagonist | 3ert | 0.00 |
| Kinases | HSP90, human heat shock protein 90 | 1uy6 | 0.00 |
| Metalloenzymes | COMT, catechol O-methyltransferase | 1h1d | 0.00 |
| Serine Proteases | Trypsin | 1bju | 0.00 |
| Other Enzymes | COX-2, cyclooxygenase-2 | 1cx2 | 0.00 |
| Metalloenzymes | ADA, adenosine deaminase | 1stw | 0.00 |
| Kinases | EGFr, epidermal growth factor receptor | 1m17 | 0.00 |
| Serine Proteases | FXa, factor Xa | 1f0r | 0.00 |
| Other Enzymes | InhA, enoyl ACP reductase | 1p44 | 0.00 |
|
|